

FACSIMILE TRANSMISSION

To DEPT of HEALTH

From B J CROWLEY

BURAGE ENF1A 506
X GRO-C

Date 15 FEBRUARY 1991

Time ✓

Fax No: 071- 972- 2818

No. of pages to follow:

PQ 1226

There is strong demand from clinicians in this country for a High Purity FVIII made from plasma provided by unpaid voluntary donors in the United Kingdom, with a solvent detergent viral inactivation step. Such a product is not currently available in the UK.

BPL is responding to this demand by licensing the appropriate technology and modifying its production facility to manufacture the product locally. For a limited period while new equipment is installed it has contracted with Messrs Kabi, a Swedish fractionator that has also licenced similar technology, to undertake part of the process on behalf of BPL from an intermediate, made from NBTS plasma.

Sweden and the UK are cosignatories to the Pharmaceutical Inspection Convention and BPL staff supervise Kabi work performed on behalf of BPL.

All BPL products are authorised under the Crown and are tested by the National Institute of Biological Standards and Control. With the expiry of Crown authority this year, BPL will be licenced under the appropriate Medicines Act and Regulations - already some of its products and facilities are so licenced.

B J Crowley
Chief Executive